What happened with INBX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Inhibrx Biosciences engineers proteins into potential cancer treatments and tests them in clinical trials. Its work centers on ozekibart (INBRX-109), studied in chondrosarcoma and other cancers, and INBRX-106, studied in non-small cell lung cancer and head and neck cancer. Neither is approved for sale.
Collaboration partners pay for rights to its technology. Its licensing income is concentrated in Scithera, which paid for licenses and the related materials and know-how. The company has also received grants, but has never earned revenue from drug sales. Equity sales and borrowing help fund development.
Future drug sales depend on successful clinical development, regulatory approval and insurance coverage and reimbursement. Inhibrx is building capabilities for a potential U.S. launch of ozekibart in chondrosarcoma, while relying on a limited number of outside manufacturers for drug supplies. Until it can generate substantial product revenue, it expects to seek additional financing or partner funding.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Bicara Therapeutics competes with Inhibrx’s INBRX-106 in head-and-neck cancer with ficerafusp alfa; both companies are testing their candidates with pembrolizumab. Watch the safety and efficacy results from Bicara’s combination trial as a comparison for INBRX-106.
Pyxis Oncology competes with Inhibrx in developing head-and-neck cancer treatments and has concentrated its development resources on MICVO. With other programs paused, MICVO’s progress is the clearest program to watch for this rivalry.
PDS Biotechnology competes with Inhibrx’s INBRX-106 in investigational head-and-neck cancer immunotherapies. PDS had no product revenue through its 2025 filing period and has funded operations mainly through share issuance and debt, so financing news matters to its ability to keep developing treatments.
Xencor competes with Inhibrx in antibody discovery, with both using modular protein engineering to design differentiated medicines. Partners pay Xencor for rights to its candidates through upfront fees, milestones and royalties; new licensing deals show which engineered antibodies attract partner backing.
Corbus Pharmaceuticals’ CRB-701 competes with Inhibrx’s INBRX-106 in head-and-neck cancer development, but uses a different mechanism: an antibody carrying a drug and targeting Nectin-4. Watch CRB-701’s head-and-neck cancer results rather than Corbus’s separate obesity program.
BioAtla competes with Inhibrx in head-and-neck cancer development using antibodies designed to bind tumor targets in acidic conditions but not in normal tissues. Its safety results are worth watching for whether this approach reduces harm to normal tissue while targeting cancer.
Molecular Partners competes with Inhibrx’s engineered-protein approach by developing protein medicines built on alternative scaffolds. Like Inhibrx, it has no commercial product sales; partners have supplied most of its revenue, so collaboration payments should not be mistaken for demand for approved medicines.
Zymeworks competes with Inhibrx in antibody discovery and engineered cancer therapies that can engage multiple targets. Partners pay Zymeworks milestones and royalties; its licensed Ziihera and pasritamig portfolio offers a concrete place to watch how its antibody technology earns money.
MacroGenics competes with Inhibrx for antibody-discovery opportunities, engineering candidates including DART molecules that bind two distinct targets. It also earns funding from collaborators and makes antibodies for outside customers, helping offset the costs of the manufacturing facility that supports its own clinical programs.
Merck’s pembrolizumab is both an existing treatment in the lung and head-and-neck cancer markets Inhibrx is pursuing and a drug being tested with INBRX-106. Merck sells pembrolizumab, while Inhibrx is developing INBRX-106 both alone and in combination with it.
Regeneron is both an antibody-discovery rival and a paying license counterparty to Inhibrx, with two patent families co-owned by the companies. Payments to extend Regeneron’s option to license technology generated $0.2 million of Inhibrx’s 2024 license revenue, making agreement updates relevant to revenue as well as competition.
Merck & Co., Inc. earningsMRK
Merck's report can show the commercial strength of Keytruda, an established treatment that Inhibrx Biosciences is testing alongside its candidate INBRX-106.
Look at Keytruda sales and Merck's comments on the drug. Strong sales would show that the established treatment INBRX-106 may be combined with or compete against remains commercially substantial, setting a high bar. Weaker sales would soften that benchmark, but would not reveal demand in Inhibrx's specific cancer indications or determine whether its combination trial will work.
Xencor, Inc. earningsXNCR
Xencor's report can show whether partners are still paying for engineered antibody candidates, a potential source of funding for Inhibrx Biosciences through licensing deals.
Look for new licensing deals and their upfront or milestone payments; collaboration income is not sales of an approved drug. Continued partner payments for rights to engineered antibodies or their development would show that outside collaboration can still fund this kind of research. No new deal or payment would leave that funding route unconfirmed, not prove that partners have lost interest.
Bicara Therapeutics Inc. earningsBCAX
If Bicara Therapeutics updates its head-and-neck cancer trial combining ficerafusp alfa with pembrolizumab, its report will offer a direct efficacy and safety comparison for Inhibrx Biosciences' INBRX-106.
If the report includes a trial update, read Bicara's efficacy signals together with safety. Convincing activity without unacceptable safety problems would make it a stronger rival in the head-and-neck cancer setting relevant to INBRX-106. Limited activity or serious safety concerns would weaken that comparison, but would not prove that INBRX-106 is effective or safe.
Inhibrx Biosciences, Inc. earningsThis company
Inhibrx Biosciences' report will show whether its lead candidate, ozekibart, is moving toward regulatory review and how quickly that progress is using cash.
Read the status of ozekibart's BLA submission alongside cash on hand and cash used in operations. Progress toward review with spending that remains manageable would show the company is turning funds into regulatory progress. A delay, or faster cash use without corresponding progress, would mean development is consuming resources without reducing regulatory uncertainty, leaving the company more reliant on financing or partnerships.
